AzTrials
AzTrials

Alzheimer DiseaseNCT03676881

Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease

An observational study of Alzheimer Disease and Dementia, run by Bruyère Health Research Institute. at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This research project will test two new computerized technologies in the detection of brain changes related to Mild Cognitive Impairment (MCI) and dementia due to Alzheimer's disease. These technologies are: 1. Read more about this study

Who is it for?
Ages 60 years and older
Conditions the study is for
Alzheimer Disease, Dementia, Neuropathology
What is being tested?
Computerized cognitive battery: Cognigram (CG) and The NeuroCatch™ Platform (NCP)
Type of treatment
Medical device
How many people
36 participants
Where
1 siteCanada
Study dates
4 Sep 2018to Dec 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: c) Diagnostic criteria: Mild Cognitive Impairment (MCI): Diagnosis of MCI in recruitment database and corroborated at baseline by: 1. Objective cognitive impairment: expressed as ≥1.5 SD below the normative mean in at least one test of the NPS tests, AND 2. MMSE >19, AND 3. Subjective Cognitive Impairment, expressed by participant and/or study partner: defined by GPCOG, AND 4. Absence of significant functional impairment: score ≤5 in the FAQ. Cognitively Normal (CN): Diagnosis of CN in recruitment database -or absence of diagnosis of MCI or dementia- and corroborated at baseline by: 1. Normal score expressed as within 1 SD from the normative mean in every test of the NPS tests, AND 2. MMSE ≥ 27

Who may be able to join

  • Age ≥ 60
  • Capable of giving consent, as stated by the University of California, San Diego Brief Assessment of Capacity to Consent (Appendix 9: UBACC)
  • Meeting the diagnostic criteria of MCI or CN (described below)
  • **For MCI subjects: availability of a Study partner, defined as a person that knows the participant for at least 5 years, has frequent contact with them (≥2 days/week) and is knowledgeable of their functioning in activities of daily living

Who cannot join

  • Significant visual, hearing, or hand-motor impairment that may interfere with the CG testing sessions or Neuropsychological Assessment
  • Currently participating in Clinical Drug Trials
  • Currently participating in multiple observational studies (≥2)
  • Meeting the DSM-IV criteria for dementia at baseline
  • Color blindness
  • No consent to UBACC administration in MCI subjects
Show all 15Show fewer
  • Non-fluent in English
  • Active Major depression, Stroke, Traumatic Brain Injury, substance abuse, any other neurological disease (with the exception of MCI in the MCI group).
  • For NCP project only:
  • In-ear hearing aid or cochlear implant, hearing device
  • Implanted pacemaker
  • Metal or plastic implants in skull
  • History of seizures
  • Allergy to rubbing alcohol or EEG gel
  • Unhealthy scalp (apparent open wounds and/or bruised or weakened skin)

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • Bruyere Research Institute

    Ottawa, Ontario, K1N 5C8

Other trials in Canada

About this study

This research project will test two new computerized technologies in the detection of brain changes related to Mild Cognitive Impairment (MCI) and dementia due to Alzheimer's disease. These technologies are:

  1. Computerized cognitive battery: Cognigram (CG) Computerized assessments have multiple advantages for the early detection of subtle changes in cognition in older adults. One of their main advantages is their higher precision when measuring accuracy and speed of responses, compared to pencil-and-paper tests. They also allow a greater reliability in measures, as tests are given in a standardized format without the interference of an evaluator. Finally, by including automatized instructions and reports, they are suitable for off-site or long-distance use. The present study aims to validate the Cognigram™ (CG) computerized cognitive tool, in a prospective and longitudinal fashion, determining if changes in the CG scores over 3, 6, 9, and 12 months, can predict progression to dementia at 1-year, 2-years, and 3-years, for patients with Mild Cognitive Impairment (MCI).
  2. The NeuroCatch™ Platform (NCP)
Read more

Event-related potentials (ERP) are non-invasive, low-cost, electrophysiological methods that allow recording of the electrical activity of the brain in vivo through an Electroencephalogram (EGG). They are free from cultural and educational influence and can provide insights into the cognitive processes. ERP could enable to detect brain changes and determine the prognosis of MCI subjects.

The NCP, an investigational medical device system developed by NeuroCatch Inc., consists of an EEG software and hardware that captures brain health information. It offers a quick (i.e., 10 minutes for EEG preparation and 6 minutes for each task of EEG recording), simple (i.e., includes only 8 electrodes), and easy-to-use solution (i.e., includes a computerized software that automatically analyzes data and outputs graphs in less than 1 minute) for the acquisition of EEG and ERP.

Read the detailed description

Rationale

Today's aging population brings an increase in the incidence of dementia. In Canada, there are approximately 564,000 persons diagnosed with dementia, with an expected two-fold increase in this number by the year 2031. In this context, the early detection and prediction of cognitive decline are both imperative for achieving the prevention and/or slowing of dementia.

Standard pencil-and-paper neuropsychological tests are pivotal for the detection and follow-up of cognitive impairment; however they are labor-intensive and require the presence of a trained neuropsychologist on-site. In this regard, computerized testing may be better suited for cognitive screening in large epidemiologic studies and for longitudinal monitoring by primary care providers, due to their higher efficiency for serial assessments and their suitability for off-site or long-distance use. At the same time, computerized testing allows for higher precision in the recording of accuracy and speed of response, with a level of sensitivity not possible in standard administrations.

A number of computerized cognitive batteries have been recently developed, though intended as research tools. There is a current demand for the validation of computerized cognitive batteries in the clinical setting. One such computerized battery is the Cognigram™ (CG), which measures processing speed, attention, working memory and learning. Previous cross-sectional studies have demonstrated the validity of CG for detecting MCI and various types of dementia. However, there is no current literature on the longitudinal validity of CG, and minimal longitudinal validation of other computerized cognitive batteries currently in existence.

On the other hand, research and medicine is moving away from behavioral responses to assess brain health (e.g. verbal responses, reaction time, etc.) and are moving toward more neuroimaging focused measures. Biological tests could enable to detect pre-dementia and determine the prognosis of MCI subjects.A promising biological test is EEG/ERP. The investigators have previously shown group differences in ERPs for patients with MCI and CN. Other studies have reported promising ERP markers of pre-dementia and progression of MCI to dementia. However, ERP can be complex to process and labor-intensive, limiting its value in the clinical setting. For example, the usual time for an ERP series measuring multiple cognitive domains typically lasts 1 hour, another 25 minutes for applying the EEG cap and ensuring all electrodes are connected, and some 30 minutes per paradigm (x2-3 paradigms).

The NeuroCatch™ Platform (NCP) offers key competitive advantages compared to other EEG platforms, having a rapid test time with automated processing, analysis and results display - benefitting patients and clinicians being significantly easier to use than current EEG systems, and it alleviates training and ramp up costs amongst EEG users. In this study, the investigators will use the NPC to explore for ERPs that could predict progression to dementia in patients with MCI. The present study will make an initial assessment of the capacity of the NCP to detect cognitive decline and predict conversion to dementia in patients with MCI.

Hypotheses:

In Cognigram, the investigators hypothesize that the following will occur:

  1. Significant differences in the CG scores at baseline will be found between MCI and CN groups ii. MCI subjects will show greater longitudinal changes than the CN subjects iii. Intra-individual Significant longitudinal changes in the CG performances at 3 and/or 6 months and/or 9 months and/or 12 months, will relate to the prospective clinical outcome at 12-months, and/or 24-months, and/or 36-months. iv. The CG will show a higher sensitivity in detecting cognitive changes, and a higher predictive power of longitudinal clinical outcome than the pencil-and-paper MoCA test.

In NeuroCatch, the investigators hypothesize that the following will occur:

  1. Significant differences in the ERP parameters (amplitude and latency of ERPs such as N100, N400, P300) at baseline will be found between MCI and CN groups II. MCI subjects will show greater longitudinal changes in ERP parameters than the CN subjects III. Intra-individual significant longitudinal changes in ERP parameters at 6 months and/or 12 months and/or 24 months, will relate to the prospective clinical outcome at 12-months, and/or 24-months, and/or 36-months.

IV. The NCP will show a higher sensitivity in detecting cognitive changes, and a higher predictive power of longitudinal clinical outcome than the pencil-and-paper MoCA test.

The objectives of the project are as follows:

  1. To discriminate CG longitudinal changes related to neural damage from normal variations in cognitively normal (CN) older adults ii. To determine if CG baseline score is related to the clinical outcome at 12-months, 24-months, and 36-months iii. To determine if intra-individual CG changes at 3, 6, 9, and 12 months, are related to the clinical outcome at 12-months, 24-months, and 36-months. iv. To compare the powers of CG and MoCA for predicting longitudinal clinical outcomes.
  2. To discriminate ERP longitudinal changes (e.g., changes in N100, N400, P300 amplitudes and latencies) related to neural damage from normal variations in cognitively normal (CN) older adults. vi. To determine if ERP baseline parameters (e.g. amplitude of N100, N400, P300) is related to the clinical outcome at 12-months, 24-months, and 36-months vii. To determine if intra-individual changes in ERP parameters at 6, 12, and 24 months, are related to the clinical outcome at 12-months, 24-months, and 36-months. viii. To compare the powers of NCP and MoCA for predicting longitudinal clinical outcomes.

For the purpose of these project, a total sample of 30 MCI and their study partners, and 30 cognitively normal subjects (CN), will be recruited. Study partners of MCI subjects will answer the functional questionnaire and the cognitive questionnaire required for defining the clinical status of participants. It is mandatory for MCI participants to have a study partner available in order to participate in this study.

For the CN project, the participants will undergo CG and Montreal Cognitive Assessment (MoCA) testing sessions at baseline, 3-months, 6-months, 9-months, and 12-months. The capacities for predicting clinical longitudinal outcomes (i.e., reversion to normal cognition, significant decline within MCI spectrum, or progression to dementia) of CG and MoCA will be compared. The clinical outcome will be assessed using a Neuropsychological battery, a functional assessment and a brief cognitive questionnaire at baseline, 12-months, 24-months and 36-months. It is expected that changes in CG scores will be sensitive to cognitive decline, allowing an early prediction of progression of the cognitive impairment.

For the NCP project, the participants will undergo NCP (Appendix 14: NCP) and MoCA testing sessions at baseline, 6-months, 12-months, 24-months, and 36-months. The capacities for predicting clinical outcomes (i.e., reversion to normal cognition, significant decline within MCI spectrum, or progression to dementia) of the NCP and MoCA tests will be compared. The clinical outcome will be assessed using a Neuropsychological battery, a functional assessment and a brief cognitive questionnaire at baseline, 12-months, 24-months, and 36-months. It is expected that changes in ERP will be sensitive to cognitive decline, allowing an early prediction of progression of the cognitive impairment.

Prospective longitudinal validation, if demonstrated, would greatly increase confidence in using CG and NCP in a clinical setting for the assessment of MCI patients and would allow early prediction of future clinical outcomes. This could help to develop preventive therapeutic strategies, while providing additional time for patients and their families to prepare for the future (e.g., financial arrangements, treatment options, and community services). CG and NCP would be of greatest use in primary care, where multiple constraints make cognitive assessments problematic (e.g., lack of time to perform cognitive testing, and lack of access to expensive neuropsychological testing not covered by OHIP) and EEG/ERP assessments prohibitive (e.g., lack of time to perform EEG, lack of access to trained experts for analyzing and interpreting the results of the EEG/ERP).

Being tested
Computerized cognitive battery: Cognigram (CG), The NeuroCatch™ Platform (NCP)
Medical subject headings
Alzheimer Disease, Dementia, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Computerized cognitive battery: Cognigram (CG)Device

    is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.

  • The NeuroCatch™ Platform (NCP)Device

    the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.

Study groups in NCT03676881
Study groupRoleWhat they receive
Mild Cognitive Impairment (MCI)30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
Receives: Device: Computerized cognitive battery: Cognigram (CG); Device: The NeuroCatch™ Platform (NCP)
Cognitively normal subjects (CN)30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
Receives: Device: Computerized cognitive battery: Cognigram (CG); Device: The NeuroCatch™ Platform (NCP)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. CG scores (accuracy and reaction speed)

    The standard scores are presented on a linear scale ranging between 0-150. This scale is broken down into three categories that reflect performance: Normal (90-150), Borderline (80-89), Abnormal (0-79).

    Measured: Baseline visit during year 1

  2. MoCA scores

    The total score is 30 points; a score of 26 or above is considered normal.

    Measured: Baseline visit during year 1

  3. ERP´s amplitudes for Auditory sensation (N100)

    mean and standard deviation in microvolt (μV).

    Measured: Baseline visit during year 1

  4. ERP´s amplitude for Cognitive processing (N400)

    mean and standard deviation in microvolt (μV)

    Measured: Baseline visit during year 1

  5. ERP´s amplitude for Basic Attention (P300)

    mean and standard deviation in microvolt (μV)

    Measured: Baseline visit during year 1.

  6. ERP´s latency for Auditory sensation (N100)

    means and standard deviations in milliseconds (ms).

    Measured: Baseline visit during year 1.

  7. ERP´s latency for Cognitive processing (N400)

    means and standard deviations in milliseconds (ms).

    Measured: Baseline visit during year 1.

  8. ERP´s latency for Basic Attention (P300)

    means and standard deviations in milliseconds (ms).

    Measured: Baseline visit during year 1.

  9. Longitudinal changes in CG scores

    The standard scores are presented on a linear scale ranging between 0-150. This scale is broken down into three categories that reflect performance: Normal (90-150), Borderline (80-89), Abnormal (0-79). Scores over the three year period will be compared.

    Measured: Complete 3 year period

  10. Longitudinal changes in MoCA scores

    The total score is 30 points; a score of 26 or above is considered normal. Scores over the three year period will be compared.

    Measured: Complete 3 year period

  11. Longitudinal change in Mini-mental state examination (MMSE)

    Change is being assessed. MMSE - any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.

    Measured: baseline, 12 months, 24 months, and 36 months follow ups

  12. Longitudinal change in FAQ

    Change is being assessed. Sum scores (range 0-30). Cutpoint of 9 (dependent in 3 or more activities) is recommended to indicate impaired function and possible cognitive impairment.

    Measured: baseline 12 months, 24 months, and 36 months follow ups

  13. Longitudinal change in GPCOG scores

    Change is being assessed. A scale for rating the perceived impact of the cognitive difficulties in daily life functions. Ratings go from 0 (no interference) to 4 (extreme interference).

    Measured: baseline 12 months, 24 months, and 36 months follow ups

  14. Longitudinal change in Rey-Osterrieth Complex Figure test (RCFT)

    Change is being assessed (copy, immediate and delayed recall). RCFT : scoring drawings based on the widely used 36-point scoring system. The same scoring criteria apply to all three drawing trials. Each of the 18 scoring units is scored based on accuracy and placement criteria. Unit scores range from two (accurately drawn, correctly placed) to zero (inaccurately drawn, incorrectly placed, unrecognizable, omitted).

    Measured: baseline, 12 months, 24 months, and 36 months follow ups

  15. Longitudinal change in Hopkins Verbal Learning test (HVLT-R)

    Change is being assessed. HVLT-R : Raw scores are derived for Total score is the total correct recall of the 3 learning trials (3 trials, 12 items, max score = /36) (0-36), Delayed Recall is out of 12 (max 12) (0-12), Retention (percent retained) is the total recalled at delay (max 12) divided by the best score on trial 2 or 3. Score range is 0% or better. Recognition Discrimination Index is the number of hits minus the number of false positive identifications. Max score is 12 (ie 12 hits, no intrusions).

    Measured: baseline, 12 months, 24 months, and 36 months follow ups

  16. Longitudinal change in Trail Making Tests A and B

    Change is being assessed.Trail making A \& B average time is 29 \& 75 seconds, >78 \& >273 seconds considered deficient, respectively.

    Measured: baseline, 12 months, 24 months, and 36 months follow ups

  17. Longitudinal change in Semantic Verbal Fluency test (animals).

    Change is being assessed. Semantic verbal fluency on animals based on most productive number of animals named in 60 seconds.

    Measured: baseline, 12 months, 24 months, and 36 months follow ups

  18. Longitudinal change in ERP´s amplitudes for Auditory sensation (N100)

    Change is being assessed. Means and standard deviations in microvolt (μV).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups.

  19. Longitudinal change in ERP´s amplitudes for Cognitive processing (N400)

    Change is being assessed. Means and standard deviations in microvolt (μV).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups.]

  20. Longitudinal change in ERP´s amplitudes for Basic Attention (P300)

    Change is being assessed. Means and standard deviations in microvolt (μV).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups.]

  21. Longitudinal change in ERP´s latencies for Auditory sensation (N100)

    Change is being assessed. Means and standard deviations in milliseconds (ms).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups

  22. Longitudinal change in ERP´s latencies for Cognitive processing (N400)

    Change is being assessed. Means and standard deviations in milliseconds (ms).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups

  23. Longitudinal change in ERP´s latencies for Basic Attention (P300)

    Change is being assessed. Means and standard deviations in milliseconds (ms).

    Measured: baseline, 6 months, 12 months, 24 months, and 36 months follow ups

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2018
  2. Study start4 Sep 2018
  3. Primary completionDec 2021 (estimated)
  4. Study completionDec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03676881
Sponsor's protocol ID
M16-17-032)
Status last verified
Jan 2020
First submitted
4 Sep 2018
Last updated
14 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Only the EEG results will be shared with the manufacturer of the NeuroCatch Platform device (HealthTech Connex, Vancouver).

Publications

  • Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement. 2008 Nov;4(6):428-37. doi: 10.1016/j.jalz.2008.07.003.

    PubMed 19012868

  • Manuel DG, Garner R, Fines P, Bancej C, Flanagan W, Tu K, Reimer K, Chambers LW, Bernier J. Alzheimer's and other dementias in Canada, 2011 to 2031: a microsimulation Population Health Modeling (POHEM) study of projected prevalence, health burden, health services, and caregiving use. Popul Health Metr. 2016 Nov 3;14:37. doi: 10.1186/s12963-016-0107-z. eCollection 2016.

    PubMed 27822143

  • Mielke MM, Machulda MM, Hagen CE, Edwards KK, Roberts RO, Pankratz VS, Knopman DS, Jack CR Jr, Petersen RC. Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. Alzheimers Dement. 2015 Nov;11(11):1367-76. doi: 10.1016/j.jalz.2015.01.008. Epub 2015 Apr 6.

    PubMed 25858683

  • Gates NJ, Kochan NA. Computerized and on-line neuropsychological testing for late-life cognition and neurocognitive disorders: are we there yet? Curr Opin Psychiatry. 2015 Mar;28(2):165-72. doi: 10.1097/YCO.0000000000000141.

    PubMed 25602241

  • Maruff, P., Lim, Y. Y., Ames, D., Ellis, K., Pietrzak, R., Savage, G., ... & Villemagne, V. (2013). Clinical utility of the cogstate brief battery in Alzheimer's disease-related memory impairment. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 9, 636-P637.

  • Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Snyder, P. J., Ames, D., Ellis, K. A., ... & Maruff, P. (2014). Utility of the Cognigram brief battery in assessing cognitive changes associated with AB and APOE genotype in preclinical Alzheimer's Disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 10(4), 429-430.

  • Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc. 2002 Jan;8(1):58-71.

    PubMed 11843075

  • Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323-9. doi: 10.1093/geronj/37.3.323.

    PubMed 7069156

  • American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC

  • Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007 Aug;64(8):966-74. doi: 10.1001/archpsyc.64.8.966.

    PubMed 17679641

  • Maruff P, Collie A, Darby D, Weaver-Cargin J, Masters C, Currie J. Subtle memory decline over 12 months in mild cognitive impairment. Dement Geriatr Cogn Disord. 2004;18(3-4):342-8. doi: 10.1159/000080229. Epub 2004 Aug 13.

    PubMed 15316183

  • Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002 Oct 8;59(7):1042-6. doi: 10.1212/wnl.59.7.1042.

    PubMed 12370459

  • Darby DG, Pietrzak RH, Fredrickson J, Woodward M, Moore L, Fredrickson A, Sach J, Maruff P. Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimers Dement. 2012;8(2):95-104. doi: 10.1016/j.jalz.2010.12.009.

    PubMed 22404851

  • Howe AS, Bani-Fatemi A, De Luca V. The clinical utility of the auditory P300 latency subcomponent event-related potential in preclinical diagnosis of patients with mild cognitive impairment and Alzheimer's disease. Brain Cogn. 2014 Apr;86:64-74. doi: 10.1016/j.bandc.2014.01.015. Epub 2014 Feb 22.

    PubMed 24565814

  • Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H; North American Alzheimer's Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2012 Jul;33(7):1203-14. doi: 10.1016/j.neurobiolaging.2010.10.019. Epub 2010 Dec 14.

    PubMed 21159408

Questions about this trial

What is this clinical trial studying?

An observational study of Alzheimer Disease and Dementia, run by Bruyère Health Research Institute. at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

CG scores (accuracy and reaction speed) (time frame: Baseline visit during year 1). The study lists 23 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03676881, which also lists 21 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in